Vectofusin®-1

Vectofusin-1 is a non-toxic histidine-rich amphipathic peptide which acts as viral transduction enhancer. Unlike recombinant fibronectin, it does not have to be precoated on cell culture surfaces, thus streamlining the transduction process.

Discover also our MACS® GMP Vectofusin-1 for ex vivo cell processing and manufacturing.

... read more

Related products for Vectofusin®-1

Specifications for Vectofusin®-1
Overview

Vectofusin-1 is a non-toxic histidine-rich amphipathic peptide which acts as viral transduction enhancer. Unlike recombinant fibronectin, it does not have to be precoated on cell culture surfaces, thus streamlining the transduction process.

Discover also our MACS® GMP Vectofusin-1 for ex vivo cell processing and manufacturing.

Detailed product information
Background information

Gene transfer into suspension cells such as T cells or hematopoietic stem cells using retroviral vectors has several therapeutic applications ranging from monogenic diseases, infectious diseases, and cancer. Viral transduction of suspension cells using retroviral vectors is often inefficient and requires the use of transduction enhancers. Vectofusin-1 is a fully synthetic non-toxic cationic amphipathic peptide with viral transduction enhancing capacity, enabling higher transduction levels with low amounts of retroviral vector. Vectofusin-1 promotes the entry of several retroviral pseudotypes into target cells when added to the culture medium.

Applications
  • Enhancement of lentiviral transduction
  • Enhancement of retroviral transduction
Product data and images for Vectofusin®-1
Figure 1

Human T cells were transduced with gamma-retroviral vectors encoding GFP in the presence of Vectofusin-1. Transduction was performed either at 37 °C in an incubator (static), or the T cells were centrifuged at 400×g for 2 hours at 32 °C (spin) before transfer to 37 °C. GFP expression was analyzed on day 7 of cultivation using a MACSQuant® Analyzer. T cell viability was assessed by flow cytometry using Viobility™ Fixable Dye.

Citations for Vectofusin®-1
Publications
  1. Ingrao, D. et al. (2014) Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Hum Gene Ther Methods 25 (1): 48-56
  2. Fenard, D. et al. (2013) Infectivity enhancement of different HIV-1-based lentiviral pseudotypes in presence of the cationic amphipathic peptide LAH4-L1. J. Virol. Methods 189 (2): 375-378